# Cofactor Genomics

Cofactor Genomics is an Asset Manager based in St. Louis, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** St. Louis, United States
- **Region:** North America
- **Address:** St. Louis, MO, United States
- **Assets under management:** Undisclosed
- **Website:** cofactorgenomics.com
- **LinkedIn:** https://www.linkedin.com/company/cofactorgenomics

## Regulatory record

- **Reports private funds:** No

## About

The Leaders in RNA | Cofactor Genomics’s mission is to create diagnostics that have the ability to predict the patients that can benefit from immunotherapies. Using more insightful multidimensional biomarkers created with RNA and machine learning, Cofactor’s diagnostics offer greater predictive power than any current test. Instead of searching for isolated, single-analyte biomarkers or DNA mutations, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response at the site of a tumor.

## Sectors

- Digital Health
- AI/ML

## People

- Douglas Adkins — M.D. (Study Lead)

## Questions

### What is OncoPrism and how does it work?

OncoPrism is Cofactor Genomics' predictive diagnostic assay. It uses RNA sequencing to analyze multidimensional biomarkers from tumor biopsies, predicting a patient's response to immunotherapy before treatment begins (per firm website).

### What is the PREDAPT Trial?

The PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial is a national study led by Cofactor. It evaluates OncoPrism across 11 solid tumor cancers and includes more than 24 healthcare systems as partners (per firm website).

### Which cancer types does Cofactor target?

Cofactor's diagnostic pipeline includes 11 solid tumor cancers: Cervical, Colorectal, Esophageal Squamous Cell, Head & Neck Squamous Cell, Hepatocellular, Non-Small-Cell Lung, Renal Cell, Small Cell Lung, Triple-Negative Breast, and Urothelial Carcinoma (per firm website).

### Who leads the clinical studies at Cofactor Genomics?

Douglas Adkins, M.D., led the study on OncoPrism. The company does not publicly list its executive team or CEO (per firm website).

### Does Cofactor Genomics have named investors or financial backers?

Cofactor's website lists an 'Investors' section but does not name specific backers or disclose funding amounts. No AUM or deployment figures are available.

### How does Cofactor's approach differ from other diagnostic companies?

Cofactor uses multidimensional RNA-based biomarkers rather than single-analyte tests. This platform aims to provide a more accurate prediction of immunotherapy response (per firm website).

### Can researchers participate in Cofactor's studies?

Yes, Cofactor invites medical oncologists, pathologists, and clinical researchers to join its sponsored retrospective or prospective studies. Full support is provided (per firm website).

## Related profiles

- [AHAlife.com](https://altss.com/profile/ahalifecom)
- [SFP Capital](https://altss.com/profile/sfp-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cofactor-genomics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology